scispace - formally typeset
V

Vicky L. Baillie

Researcher at University of the Witwatersrand

Publications -  53
Citations -  8735

Vicky L. Baillie is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 35 publications receiving 4077 citations. Previous affiliations of Vicky L. Baillie include South African Medical Research Council & Medical Research Council.

Papers
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Ting Shi, +138 more
- 02 Sep 2017 - 
TL;DR: In this paper, the authors estimated the incidence and hospital admission rate of RSV-associated acute lower respiratory infection (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions.
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

TL;DR: In this article , a new SARS-CoV-2 viral isolate Omicron-B.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants, leading to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Journal ArticleDOI

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

TL;DR: In this paper, the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.617.1 and B.1.2 has been studied.